ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,929.99
      -0.89%
      US Tech 100
      20,461.20
      -1.60%
      Dow Jones
      43,408.44
      -0.12%
      Brent Oil
      73.915
      -0.77%
      Bitcoin
      86,926.29
      -4.94%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. BioCryst Pharmaceuticals Inc (BCRX) Quote

      BioCryst Pharmaceuticals Inc

      BioCryst Pharmaceuticals Inc (BCRX)

      NASDAQ
      8.075
      -0.215
      ( -2.59% )
      Updated: 10:26:34
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      8.075
      Bid
      8.07
      Ask
      8.08
      Volume
      664,310
      7.935 Day's Range 8.44
      4.03 52 Week Range 9.50
      Market Cap
      1.673B
      Previous Close
      8.29
      Open
      8.44
      Last Trade
      9
      @
      8.075
      Last Trade Time
      10:26:40
      Financial Volume
      $ 5,472,134
      VWAP
      8.2373
      Average Volume (3m)
      2,533,694
      Shares Outstanding
      207,132,571
      Dividend Yield
      -
      PE Ratio
      -7.58
      Earnings Per Share (EPS)
      -1.09
      Revenue
      331.41M
      Net Profit
      -226.54M

      About BioCryst Pharmaceuticals Inc

      BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, ... BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.biocryst.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      BioCryst Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BCRX. The last closing price for BioCryst Pharmaceuticals was $8.29. Over the last year, BioCryst Pharmaceuticals shares have traded in a share price range of $ 4.03 to $ 9.50.

      BioCryst Pharmaceuticals currently has 207,132,571 shares outstanding. The market capitalization of BioCryst Pharmaceuticals is $1.72 billion. BioCryst Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.58.

      Ask ADVFN Intelligence (AI)

      BCRX Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 24 2025
      BCRX (-2.59%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 13 2025
      BCRX (-2.59%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.305-13.91257995749.389.57.93548932749.07749299CS
      40.0650.8114856429468.019.57.5432582128.74262333CS
      120.787510.80617495717.28759.56.9625336948.12433006CS
      26-0.085-1.041666666678.169.56.84521901177.91967169CS
      522.37541.66666666675.79.54.0327473766.72676869CS
      156-8.505-51.296743063916.5818.64.0330523618.65495513CS
      2605.625229.5918367352.4519.991.5841279738.26268604CS

      BCRX - Frequently Asked Questions (FAQ)

      What is the current BioCryst Pharmaceuticals share price?
      The current share price of BioCryst Pharmaceuticals is $ 8.075
      How many BioCryst Pharmaceuticals shares are in issue?
      BioCryst Pharmaceuticals has 207,132,571 shares in issue
      What is the market cap of BioCryst Pharmaceuticals?
      The market capitalisation of BioCryst Pharmaceuticals is USD 1.72B
      What is the 1 year trading range for BioCryst Pharmaceuticals share price?
      BioCryst Pharmaceuticals has traded in the range of $ 4.03 to $ 9.50 during the past year
      What is the PE ratio of BioCryst Pharmaceuticals?
      The price to earnings ratio of BioCryst Pharmaceuticals is -7.58
      What is the cash to sales ratio of BioCryst Pharmaceuticals?
      The cash to sales ratio of BioCryst Pharmaceuticals is 5.18
      What is the reporting currency for BioCryst Pharmaceuticals?
      BioCryst Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for BioCryst Pharmaceuticals?
      The latest annual turnover of BioCryst Pharmaceuticals is USD 331.41M
      What is the latest annual profit for BioCryst Pharmaceuticals?
      The latest annual profit of BioCryst Pharmaceuticals is USD -226.54M
      What is the registered address of BioCryst Pharmaceuticals?
      The registered address for BioCryst Pharmaceuticals is 2711 CENTERVILLE ROAD, NEW CASTLE, WILMINGTON, DELAWARE, 19808
      What is the BioCryst Pharmaceuticals website address?
      The website address for BioCryst Pharmaceuticals is www.biocryst.com
      Which industry sector does BioCryst Pharmaceuticals operate in?
      BioCryst Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SXTCChina SXT Pharmaceuticals Inc
      $ 3.88
      (361.90%)
      		299.45k
      ONVOOrganovo Holdings Inc
      $ 1.27
      (244.17%)
      		146.02M
      WAFUWah Fu Education Group Ltd
      $ 5.51
      (207.82%)
      		83.35M
      JTAIJet AI Inc
      $ 9.1094
      (54.92%)
      		10.1M
      FMTOFemto Technologies Inc
      $ 5.25
      (46.78%)
      		31.73M
      YYAIConnexa Sports Technologies Inc
      $ 0.7201
      (-43.30%)
      		3.54M
      DGNXDiginex Ltd
      $ 42.27
      (-39.04%)
      		104.44k
      ATPCAgape ATP Corporation
      $ 0.9901
      (-38.12%)
      		1.1M
      CLNEClean Energy Fuels Corp
      $ 1.9099
      (-29.52%)
      		3.57M
      CYCUCycurion Inc
      $ 0.7112
      (-28.09%)
      		3.15M
      ONVOOrganovo Holdings Inc
      $ 1.27
      (244.17%)
      		151.08M
      WAFUWah Fu Education Group Ltd
      $ 5.51
      (207.82%)
      		83.85M
      NVDANVIDIA Corporation
      $ 124.545
      (-4.40%)
      		80.8M
      DMNDamon Inc
      $ 0.3286
      (8.13%)
      		59.39M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 14.91
      (-13.96%)
      		55M

      BCRX Discussion

      View Posts
      rosemountbomber rosemountbomber 23 hours ago
      What is this company doing?  No wonder Denner bailed.  
      👍️0
      Monksdream Monksdream 2 days ago
      BCRX 10Q due MONDAY 2/24
      👍️0
      rosemountbomber rosemountbomber 1 month ago
      What is going on here, stock price whipsawed from one day to the next. Doesn't seem like any rhyme or reason.
      👍️0
      Monksdream Monksdream 2 months ago
      BCRX, under $8
      👍️0
      Monksdream Monksdream 4 months ago
      BCRX under $10

      👍️0
      Monksdream Monksdream 7 months ago
      BCRX under $8
      👍️0
      Monksdream Monksdream 10 months ago
      BCRX new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      BCRX new 52 lo
      👍️0
      Monksdream Monksdream 10 months ago
      BCRX new 52 week lo
      👍️0
      Monksdream Monksdream 11 months ago
      BCRX under $10
      👍️0
      Monksdream Monksdream 1 year ago
      BCRX 10Q 2/26
      👍️0
      Calcumad Calcumad 1 year ago
      It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper
      👍️0
      james kent james kent 2 years ago
      when will it turn around?
      👍️0
      james kent james kent 2 years ago
      when will it turn around?
      👍️0
      ttubular ttubular 2 years ago
      Huge buys in AH
      👍️0
      VivaLasVegas VivaLasVegas 2 years ago
      Why is this symbol now taking a digger with all the rest?
      What did Stoney do or not do?
      👍️0
      ttubular ttubular 3 years ago
      6:58a ET 8/4/2022 - Globe Newswire
      BioCryst Resumes Enrollment in BCX9930 Clinical Program
      Mentioned: BCRX
      EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

      Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.
      👍️0
      conix conix 3 years ago
      BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

      BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.
      👍️0
      Cosa Cosa 3 years ago
      I guess it was perfect timing in a way...
      👍️0
      Cosa Cosa 3 years ago
      I reduced my position here to buy more AUPH (facepalm)
      👍️0
      starkd748 starkd748 3 years ago
      13.90s pullback yesss
      👍️0
      starkd748 starkd748 3 years ago
      Overbought pullback in progress TA saves money
      👍️0
      Limey42 Limey42 3 years ago
      You were saying? LMFAO!!!!!!!!
      👍️0
      game7alcs game7alcs 3 years ago
      BCRX just on CNBC for large call volume action
      👍️0
      starkd748 starkd748 3 years ago
      Burnt to a crisp rsi enjoy
      👍️0
      starkd748 starkd748 3 years ago
      Lmfao the rsi is 100 pullback in progress
      👍️0
      ttubular ttubular 3 years ago
      Understatement
      👍️0
      Limey42 Limey42 3 years ago
      This company is a juggernaut!
      👍️0
      plexrec plexrec 3 years ago
      Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA
      👍️0
      ezyE ezyE 3 years ago
      Great buying opportunity.
      Shouldn't be this low.
      👍️0
      easyrider1 easyrider1 3 years ago
      What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.
      👍️0
      easyrider1 easyrider1 3 years ago
      Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more
      👍️0
      starkd748 starkd748 3 years ago
      Might buy some options here
      👍️0
      easyrider1 easyrider1 3 years ago
      Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.
      👍️0
      MZlu MZlu 3 years ago
      I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
      - They won a prize for R&D
      - They won a prize for marketing
      - Barron's did a favorable mention of the Company
      Looks like the big boys are shifting the narrative.
      👍️0
      easyrider1 easyrider1 3 years ago
      First sign of life….someone realizes that this a buy
      👍️0
      Deano361 Deano361 3 years ago
      Yeah been 18 months now and holding for me . I thin pnh results soon will help us
      👍️0
      easyrider1 easyrider1 3 years ago
      I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

      This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.
      👍️0
      Deano361 Deano361 3 years ago
      Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials
      👍️0
      Cosa Cosa 3 years ago
      The sharp increase in revenue is what got my attention!
      👍️0
      Cosa Cosa 3 years ago
      "Facepalm" I jinxed you guys.
      👍️0
      bhulkupk bhulkupk 3 years ago
      Hi Cosa, welcome…
      👍️0
      Deano361 Deano361 3 years ago
      Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.
      👍️0
      Cosa Cosa 3 years ago
      Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.
      👍️0
      easyrider1 easyrider1 3 years ago
      Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

      More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside
      👍️0
      Deano361 Deano361 3 years ago
      Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year
      👍️0
      bhulkupk bhulkupk 3 years ago
      Oh okay, so I can buy some for long term? Thanks in advance.
      👍️0
      Deano361 Deano361 3 years ago
      It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!
      👍️0
      bhulkupk bhulkupk 3 years ago
      How?
      👍️0

      Your Recent History

      NASDAQ
      BCRX
      BioCryst Pharmaceuticals
      AQSE
      VUSC.GB
      Vanguard Funds
      BIT
      P1U6D8
      BNP Paribas Issuance
      BIT
      P13ZB1
      BNP Paribas Issuance
      BIT
      P170U4
      BNP Paribas Issuance
      BIT
      JAGA
      ETF
      BIT
      UB5M1Y
      Unicredit Bank
      BIT
      P1U5S8
      BNP Paribas Issuance
      BIT
      UB591M
      Unicredit Bank
      BIT
      UB9P76
      Unicredit Bank
      BIT
      UC0SF0
      Unicredit Bank
      BIT
      P12AO9
      BNP PARIBAS ISSUANCE
      BIT
      P1SVD3
      BNP Paribas Issuance
      BIT
      P1T508
      BNP Paribas Issuance
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads